Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PYM50028

Known as: PYM 50028, PYM-50028 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
T his meeting was my first visit to San Diego – if I'd have known better I would have brought my wetsuit and surfboard (I've… Expand
Review
2015
Review
2015
Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but… Expand
  • table 1
  • table 2
2013
2013
The purpose of this paper is to study the effect of smilagenin (SMI) (PYM50028), a sapogenin compound originally identified from… Expand
Review
2013
Review
2013
  • P. Worth
  • Clinical medicine
  • 2013
  • Corpus ID: 46221158
Parkinson's disease is a common, progressive, debilitating disease with substantial physical, psychological and social… Expand
  • table 1
  • table 2
Review
2012
Review
2012
Currently the mainstay of Parkinson's disease (PD) therapy is the pharmacological replacement of the loss of the dopaminergic… Expand
2010
2010
  • D. Grosset
  • IDrugs : the investigational drugs journal
  • 2010
  • Corpus ID: 6972601
The XVIII World Federation of Neurology (WFN) World Congress on Parkinson's Disease and Related Disorders, held in Miami, FL, USA… Expand
2010
2010
The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new… Expand
Highly Cited
2008
Highly Cited
2008
Many experimental data support the enhancement of neurotrophic factors as a means to modify neurodegeneration in Parkinson's… Expand
2005
2005
  • A. Harvey
  • IDrugs : the investigational drugs journal
  • 2005
  • Corpus ID: 41752843
The meeting covered many aspects of the use of natural products in drug discovery and development. The historical and current… Expand